An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease
- Conditions
- Crohn Disease
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT03362736
- Locations
- 🇧🇷
Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP, Ribeirao Preto, Brazil
🇧🇷Universidade Federal do Rio de Janeiro - Faculdade de Medicina, Rio de Janeiro, Brazil
🇧🇷Hospital Nossa Senhora Das Gracas, Curitiba, Brazil
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis
- Conditions
- Crohn DiseaseUlcerative Colitis
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT03358706
- Locations
- 🇩🇪
Universitatsklinikum Essen, Essen, Germany
🇩🇪Universitatsklinikum Freiburg, Freiburg, Germany
🇩🇪Universitatsklinikum Bonn, Bonn, Germany
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT03357952
- Locations
- 🇧🇪
Algemeen Ziekenhuis Klina, Brasschaat, Belgium
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇧🇪UZBrussel, Brussel, Belgium
A Study of Paliperidone Palmitate 6-Month Formulation
- Conditions
- Schizophrenia
- Interventions
- Drug: PP1MDrug: PP6MDrug: PP3M 350 mg eq.Other: PlaceboDrug: PP3M 525 mg eq.
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 841
- Registration Number
- NCT03345342
- Locations
- 🇧🇬
State Psychiatric HospitalDr.Georgi Kissiov, Radnevo, Bulgaria
🇨🇿NeuropsychiatrieHK, s.r.o., Hradec Kralove-Vekose, Czechia
🇧🇬Centre for Mental Health Prof.N.Shipkovenski EOOD, Sofia, Bulgaria
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-64991524 Dose Level 2Drug: JNJ-64991524 Dose Level 6Drug: JNJ-64991524 Dose Level 3Drug: JNJ-64991524 Dose Level 4Drug: JNJ-64991524 Dose Level 5Drug: JNJ-64991524 Dose Level 1Drug: PlaceboDrug: JNJ-64991524 Dose Level 9Drug: JNJ-64991524 Dose Level 7Drug: JNJ-64991524 Dose Level 8
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 86
- Registration Number
- NCT03346122
- Locations
- 🇧🇪
SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerpen, Belgium
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 7
- Registration Number
- NCT03332459
- Locations
- 🇯🇵
National Hospital Organization Niigata National Hospital, Niigata, Japan
🇯🇵Fukuyama City Hospital, Fukuyama, Japan
🇯🇵National Hospital Organization Beppu Medical Center, Oita, Japan
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 7
- Registration Number
- NCT03333317
- Locations
- 🇯🇵
Takatsuki General Hospital, Osaka, Japan
🇯🇵Shikoku Medical Center for Children and Adults, Zentsuji, Japan
🇵🇱Plejady Medical Center, Malopolska, Poland
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT03320707
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
- Conditions
- Depressive Disorder, Major
- Interventions
- Drug: Placebo Matching to JNJ-42847922Drug: Placebo Matching to Quetiapine XRDrug: Selective Serotonin Reuptake Inhibitor (SSRI)Drug: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 107
- Registration Number
- NCT03321526
- Locations
- 🇺🇸
NoesisPharma Research, Phoenix, Arizona, United States
🇺🇸Clinical Research Consortium Arizona, Tempe, Arizona, United States
🇺🇸Woodland Research Northwest, Rogers, Arkansas, United States
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
- Conditions
- Smoldering Multiple Myeloma
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 390
- Registration Number
- NCT03301220
- Locations
- 🇦🇺
Austin Hospital, Heidelberg, Australia
🇦🇺Calvary Mater Newcastle Hospital, Waratah, Australia
🇦🇺The Perth Blood Institute, West Perth, Australia